Karen Anderson Sells 10,043 Shares of Centessa Pharmaceuticals (NASDAQ:CNTA) Stock

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) insider Karen Anderson sold 10,043 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $28.10, for a total value of $282,208.30. Following the completion of the transaction, the insider owned 62,085 shares of the company’s stock, valued at approximately $1,744,588.50. The trade was a 13.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Centessa Pharmaceuticals Stock Performance

Shares of Centessa Pharmaceuticals stock traded down $0.24 on Wednesday, reaching $28.71. 1,835,638 shares of the company were exchanged, compared to its average volume of 1,195,469. The firm has a market cap of $4.19 billion, a price-to-earnings ratio of -15.69 and a beta of 1.55. Centessa Pharmaceuticals PLC Sponsored ADR has a 1-year low of $9.60 and a 1-year high of $30.58. The company has a debt-to-equity ratio of 0.36, a quick ratio of 10.57 and a current ratio of 10.56. The company’s 50-day moving average is $24.92 and its two-hundred day moving average is $24.51.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on CNTA. B. Riley Financial boosted their price target on shares of Centessa Pharmaceuticals from $33.00 to $42.00 and gave the company a “buy” rating in a report on Monday, December 1st. Truist Financial boosted their price objective on Centessa Pharmaceuticals from $33.00 to $38.00 and gave the stock a “buy” rating in a research report on Thursday, January 29th. Oppenheimer raised their target price on Centessa Pharmaceuticals from $40.00 to $62.00 and gave the company an “outperform” rating in a research report on Wednesday, December 10th. Guggenheim lifted their target price on Centessa Pharmaceuticals from $28.00 to $43.00 and gave the company a “buy” rating in a research note on Tuesday, November 18th. Finally, Piper Sandler reiterated an “overweight” rating on shares of Centessa Pharmaceuticals in a research report on Friday, January 16th. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $39.80.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in CNTA. Avoro Capital Advisors LLC lifted its position in Centessa Pharmaceuticals by 34.7% in the fourth quarter. Avoro Capital Advisors LLC now owns 14,555,555 shares of the company’s stock worth $364,034,000 after purchasing an additional 3,747,475 shares during the period. Adage Capital Partners GP L.L.C. increased its position in shares of Centessa Pharmaceuticals by 12.4% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 11,281,741 shares of the company’s stock valued at $282,156,000 after purchasing an additional 1,246,741 shares during the period. Farallon Capital Management LLC increased its position in shares of Centessa Pharmaceuticals by 24.1% during the 4th quarter. Farallon Capital Management LLC now owns 5,377,068 shares of the company’s stock valued at $134,480,000 after purchasing an additional 1,045,750 shares during the period. Siren L.L.C. raised its stake in shares of Centessa Pharmaceuticals by 24.8% in the 4th quarter. Siren L.L.C. now owns 4,027,517 shares of the company’s stock worth $100,728,000 after buying an additional 800,000 shares in the last quarter. Finally, Commodore Capital LP raised its stake in shares of Centessa Pharmaceuticals by 39.3% in the 2nd quarter. Commodore Capital LP now owns 3,298,289 shares of the company’s stock worth $43,340,000 after buying an additional 930,711 shares in the last quarter. 82.01% of the stock is currently owned by institutional investors.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.